ruzinurad (SHR 4640) / Jiangsu Hengrui Pharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ruzinurad (SHR 4640) / Jiangsu Hengrui Pharma
NCT03185793: Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia

Completed
2
198
RoW
Placebo, SHR4640, benzbromarone
Jiangsu HengRui Medicine Co., Ltd.
Hyperuricemia
07/18
07/18
NCT04180982: A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia

Unknown status
2
84
NA
SHR4640 dose1 plus Febuxostat dose1, SHR4640 dose1 plus Febuxostat dose2, SHR4640 dose2 plus Febuxostat dose3
Jiangsu HengRui Medicine Co., Ltd.
Hyperuricemia
07/20
08/20
NCT05513976: Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia

Not yet recruiting
2
129
NA
SHR4640 tablet, febuxostat tablet, SHR4640 placebo tablet
Jiangsu HengRui Medicine Co., Ltd.
Primary Gout and Hyperuricemia
05/23
09/23

Download Options